|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: DAYTRANA
Summary for Tradename: DAYTRANA
|
| |||||||||
Clinical Trials for: DAYTRANAStudy of the Effect of Individualizing Daytrana Wear-times on Sleep in Children With ADHD Status: Completed Condition: Attention Deficit Hyperactivity Disorder; INSOMNIA A Study to Explore Plasma Levels of CONCERTA, Ritalin-SR and Novo-Methylphenidate ER-C in Healthy Volunteers Status: Completed Condition: Pharmacokinetics A Study Comparing Long-acting Methylphenidate (ConcertaTM) vs. Placebo in the Treatment of Memory Loss Due to HIV Status: Recruiting Condition: HIV Dementia An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder Status: Completed Condition: Attention Deficit Hyperactivity Disorder Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning Status: Terminated Condition: Brain Tumor Ritalin: Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients Status: Terminated Condition: Asthenia; Neoplasms Methylphenidate Study in Breast or Gastrointestinal Cancer Patients Status: Active, not recruiting Condition: Breast Cancer; Fatigue; Gastrointestinal Cancer A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults Status: Active, not recruiting Condition: Healthy The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease. Status: Terminated Condition: Parkinson's Disease A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in Children Status: Completed Condition: Attention Deficit Hyperactivity Disorder Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Noven Pharms Inc | DAYTRANA | methylphenidate | FILM, EXTENDED RELEASE; TRANSDERMAL | 021514 | Apr 6, 2006 | RX | No | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Noven Pharms Inc | DAYTRANA | methylphenidate | FILM, EXTENDED RELEASE; TRANSDERMAL | 021514 | Apr 6, 2006 | RX | No | 5,958,446 | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Noven Pharms Inc | DAYTRANA | methylphenidate | FILM, EXTENDED RELEASE; TRANSDERMAL | 021514 | Apr 6, 2006 | RX | No | 6,210,705 | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Noven Pharms Inc | DAYTRANA | methylphenidate | FILM, EXTENDED RELEASE; TRANSDERMAL | 021514 | Apr 6, 2006 | RX | No | 6,348,211 | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: DAYTRANA
| Drugname | Dosage | Strength | RLD | Submissiondate |
| methylphenidate | Transdermal System | 10 mg/9 hrs, 15 mg/9 hrs, 20 mg/9 hrs and 30 mg/9 hrs | Daytrana | 4/13/2011 |
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc